Guillem Pont-Espinós

Guillem Pont-Espinós

Auto-generated profile, based on publicly available information

Guillem Pont-Espinós

Department of Physiological Sciences, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GPGuillem Pont-Espinós
Guillem Pont-Espinós
APAdrià Pla-Casillanis
Adrià Pla-Casillanis
LFLaura Ferigle
Laura Ferigle
MAMarta Alonso-Gardón
Marta Alonso-Gardón
MGMarc González-Subías
Marc González-Subías
Raúl EstévezRaúl Estévez
Raúl Estévez
Megalencephalic leukoencephalopathy with subcortical cyst (MLC) is a rare leukodystrophy primarily caused by mutations in two genes: MLC1, encoding a membrane protein of unknown function, and GlialCAM, a cell adhesion molecule. Although MLC1 has been implicated in downregulating signaling pathways, its molecular mechanisms remain elusive. Recently, the orphan G-protein-coupled receptor GPRC5B was identified as a novel interactor of both GlialCAM and MLC1, with dominant heterozygous mutations found in MLC patients, suggesting that GlialCAM and MLC1 may regulate cell signaling via GPRC5B. Here, we show that GPRC5B exhibits constitutive activity, which is inhibited by MLC1, likely through interference with GPRC5B oligomerization. Conversely, GlialCAM enhances β-arrestin 2 recruitment, leading to its own mislocalization from cell-cell junctions. MLC-associated GPRC5B mutants show enhanced maturation and increased stability at the plasma membrane, retain normal constitutive activity and responsiveness to MLC1 and GlialCAM but display increased affinity for GlialCAM and localize to cell-cell junctions in its presence. Notably, coexpression of GlialCAM with these mutants does not induce GlialCAM mislocalization. We propose a model in which finely tuned interactions among GPRC5B, GlialCAM, and MLC1 regulate receptor signaling. These findings provide the first biochemical evidence of GlialCAM and MLC1 modulating GPRC5B activity, suggesting a biochemical explanation for the gain-of-function phenotype observed in GPRC5B MLC mutants. Importantly, our work supports the potential of targeting GPRC5B as a therapeutic strategy in MLC.

21 August 2026 in Glia
Verified
Journal Article
Open access
PDF file
ALAlba M. Lucart‐Sanchez
Alba M. Lucart‐Sanchez
ESEdward Sellés‐Climent
Edward Sellés‐Climent
JCJorge Navarro Calvo
Jorge Navarro Calvo
GPGuillem Pont‐Espinós
Guillem Pont‐Espinós
Jose Antonio Gomez-SanchezJose Antonio Gomez-Sanchez
Jose Antonio Gomez-Sanchez
RPRocío Pérez‐González
Rocío Pérez‐González
Extracellular vesicles (EVs) mediate intercellular communication in the central nervous system (CNS) and are emerging as biomarkers of brain health and disease. However, the molecular composition of cell type‐specific brain EVs, particularly astrocyte‐derived EVs (ADEVs), remains poorly defined. We performed comparative proteomic analysis of neuronal (NDEVs), microglial (MDEVs), and ADEVs from mouse brain using magnetic immunocapture and LC–MS/MS proteomic profiling. Each EV subtype displayed distinct molecular fingerprints. NDEVs were enriched in synaptic and neurogenesis‐related proteins (e.g., APP, SNAP25, GPR158, and BDNF), whereas MDEVs contained immune and phagocytic markers (e.g., TMEM119, CX3CR1, CD11b). Strikingly, the ADEV proteome closely mirrored the recently characterized GlialCAM interactome from leukodystrophy research, encompassing GlialCAM/MLC1 and associated partners involved in ion and water homeostasis (EAAT1/2, AQP4, GJA1), together with GPCRs such as GPRC5B. This overlap suggests that ADEVs encapsulate a molecular scaffold characteristic of astrocytic endfeet, potentially extending their signaling functions to the extracellular space. In conclusion, our study provides a detailed comparative proteomic characterization of brain cell type‐specific EVs, revealing that ADEVs contain the GlialCAM/MLC1 network and GPCRs. These findings identify candidate molecular signatures that support the future investigation of ADEVs for biomarker development and provide a proteomic framework for exploring their relationship with astrocytic endfoot biology, blood–brain barrier (BBB)‐associated pathways, and neurodegenerative disorders.

14 December 2025 in bioRxiv
Verified
Preprint
Open access
ALAlba M. Lucart-Sanchez
Alba M. Lucart-Sanchez
ESEdward Sellés-Climent
Edward Sellés-Climent
JCJorge Navarro Calvo
Jorge Navarro Calvo
GPGuillem Pont-Espinós
Guillem Pont-Espinós
Jose Antonio Gomez-SanchezJose Antonio Gomez-Sanchez
Jose Antonio Gomez-Sanchez
RPRocío Pérez-González
Rocío Pérez-González
Extracellular vesicles (EVs) mediate intercellular communication in the central nervous system (CNS) and are emerging as biomarkers of brain health and disease. However, the molecular composition of cell type-specific brain EVs, particularly astrocyte-derived EVs (ADEVs), remains poorly defined. We performed comparative proteomic analysis of neuronal (NDEVs), microglial (MDEVs), and astrocytic (ADEVs) from mouse brain using magnetic immunocapture and LC-MS/MS proteomic profiling. Each EV subtype displayed distinct molecular fingerprints. NDEVs were enriched in synaptic and neurogenesis-related proteins (e.g., APP, SNAP25, GPR158 and BDNF), whereas MDEVs contained immune and phagocytic markers (e.g., TMEM119, CX3CR1, CD11B). Strikingly, the ADEV proteome closely mirrored the recently characterized GlialCAM interactome from leukodystrophy research, encompassing GlialCAM/MLC1 and associated partners involved in ion and water homeostasis (EAAT1/2, AQP4, GJA1), together with GPCRs such as GPRC5B. This overlap suggests that ADEVs encapsulate a molecular scaffold characteristic of astrocytic endfeet, potentially extending their signaling functions to the extracellular space. In conclusion, our study provides a detailed comparative proteomic characterization of brain cell type-specific EVs, revealing that ADEVs contain the GlialCAM/MLC1 network and GPCRs. These findings highlight ADEVs as promising candidates for biomarker development and mechanistic studies of blood-brain barrier integrity and neurodegenerative disorders.

15 October 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YKYulia Kostritskaia
Yulia Kostritskaia
HGHéctor Gaitán-Peñas
Héctor Gaitán-Peñas
Sara BertelliSara Bertelli
Sara Bertelli
MAMarta Alonso-Gardón
Marta Alonso-Gardón
MKMalte Klüssendorf
Malte Klüssendorf
Raúl EstévezRaúl Estévez
Raúl Estévez
The mechanisms by which physiological signals gate the volume-regulated anion channel (VRAC) remain poorly understood. Here, we identify a GPRC5B–Fyn signaling axis that directly controls VRAC activation by targeting the essential subunit LRRC8A. We found that the orphan G protein–coupled receptor GPRC5B binds LRRC8A and recruits the Src family kinase Fyn, which in turn suppresses hypotonicity-evoked VRAC activation. Disrupting Fyn binding to GPRC5B or substituting a predicted phosphorylation site on LRRC8A (Y362) abolishes this inhibition. Across primary astrocytes and reconstituted systems, GPRC5B prevents the intersubunit conformational rearrangements associated with VRAC opening without altering basal channel expression. In astrocytes, the MLC protein MLC1 partially sequesters GPRC5B, thereby reducing the GPRC5B–LRRC8A interaction, providing a mechanistic link to VRAC dysfunction in megalencephalic leukoencephalopathy. These results reveal a receptor-kinase-channel pathway that gates VRAC through Y362-dependent modulation of LRRC8A, establishing a molecular framework for VRAC regulation and its disruption in disease.

3 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HJHanxing Jiang
Hanxing Jiang
AMAdrián Martínez-Jiménez
Adrián Martínez-Jiménez
KHKazi Amirul Hossain
Kazi Amirul Hossain
HSHaigang Song
Haigang Song
BOBorja Ochoa-Lizarralde
Borja Ochoa-Lizarralde
Ekaitz Errasti-MurugarrenEkaitz Errasti-Murugarren
Ekaitz Errasti-Murugarren
The physiological function of the human choline transporter-like protein CTL1 (SLC44A1) remains elusive despite its implication in key pathophysiological processes. Here we combine cryo-electron microscopy, native mass spectrometry, lipidomics, molecular dynamics simulations and functional assays to characterise the molecular basis of phospholipid recognition by CTL1 and explore its potential molecular role. High-resolution structures of CTL1 in both monomeric and dimeric states reveal a broad amphipathic cavity and an extracellular domain that accommodate multiple phospholipid species, identifying phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and phosphatidic acid as endogenous CTL1 ligands. Molecular dynamics simulations show spontaneous phospholipid recruitment into these conserved binding sites accompanied by membrane thinning, curvature and local phospholipid reorganisation, with membrane deformation being enhanced upon dimerisation. Functional analyses in mammalian cells and in reconstituted proteoliposomes failed to detect CTL1-mediated choline transport, supporting a function distinct from canonical choline uptake. Together, our findings suggest that CTL1 acts as a phospholipid-binding protein capable of locally deforming the membrane and provide a structural framework linking phospholipid recognition to membrane organisation. These results offer new insights into potential mechanisms underlying the altered phospholipid homeostasis associated with CTL1 dysfunction in neurological diseases and cancer.